Regulus filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC, which includes, among other things, the recommendation of Regulus’s board of directors that Regulus’s stockholders ...

The mental health and wellbeing of our people is vitally important. It is a natural extension of our company’s purpose to discover new ways to improve and extend people’s lives. Our ambition at ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

To report an adverse event or any drug related issues concerning Novartis medicinal products; please contact Novartis Patient Safety: Tel: +202 22861000 - Press 3 for reporting an adverse event.

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

For the estimated 2.8 million people 1 living with multiple sclerosis (MS) worldwide, diagnosis is life-altering and can be overwhelming. The symptoms, including loss of vision, movement and sensation ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

In today's rapidly evolving healthcare landscape, there is a profound shift in how patients approach their cancer diagnosis and treatment. Novartis has been committed to extending and improving lives ...

Fabhalta APPULSE-PNH full results build on Phase III program, reporting new data from expanded PNH population in adults switching from anti-C5 Ianalumab Phase II data in immune thrombocytopenia and ...

The world has entered a new era of cancer care – and as scientific advances have dramatically improved outcomes, patients are more informed and empowered than ever to be their own treatment advocates.

ノバルティス ファーマ株式会社（本社：東京都港区、代表取締役社長：ジョンポール・プリシーノ、以下「ノバルティス ファーマ」）は、本日、「セムブリックス ® 錠20 mg、同40 mg（一般 ...

Syftet med studien är att utvärdera effekt och säkerhet av remibrutinib (LOU064) när det ges till patienter med skovvis förlöpande multipel skleros. Studiens huvudsyfte är att ta reda på om patienter ...